|Bid||837.90 x 0|
|Ask||838.00 x 0|
|Day's Range||825.05 - 840.00|
|52 Week Range||806.25 - 1,573.60|
|PE Ratio (TTM)||20.79|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
(Reuters) - Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday. Drugmakers ...
Lupin Ltd., which makes generic antibiotics, antidepressants and heart medications for sale in the U.S., was warned by the Food and Drug Administration for repeatedly ignoring tests showing that pills ...
REUTERS - Drugmaker Lupin Ltd (LUPN.NS) said on Monday second-quarter net profit fell more than 30 percent, as regulatory scrutiny and pricing pressure in the United States, its biggest market, dampened ...
Indian drugmaker Lupin Ltd said on Monday second-quarter net profit fell more than 30 percent, as regulatory scrutiny and pricing pressure in the United States, its biggest market, dampened sales. The ...
REUTERS - Indian shares rose for a third straight session on Tuesday but the gains were capped as investors hedged their bets before September-quarter corporate results kick in later this week. The benchmark ...
While India’s largest pharmaceutical companies have seen drug approvals in the U.S. slow overall, their research and development spending has been on a run. Not so for Aurobindo Pharma Ltd.Quarter after ...
Indian drugmaker Lupin Ltd said on Wednesday first quarter profit fell 59 percent, well below analysts' estimates, as regulatory hurdles and pricing pressure in the United States, its biggest overseas market, weighed. Lupin, which specialises in oral contraceptives and drugs to treat diabetes and hypertension, said sales in the United States fell about 27 percent to 16.02 billion rupees, while domestic sales were down 1.8 percent at 9.32 billion rupees. Analysts on average expected Lupin to post a profit of 4.79 billion rupees, Thomson Reuters data showed.
To keep his anxiety under control, Peter, a 35-year-old government employee, relied for nine years on a blue-and-white pill he popped every night before bed: Cymbalta, made by Eli Lilly & Co. When a generic ...
Novartis does not need a big acquisition to kick-start growth, Chief Executive Joe Jimenez told investors on Wednesday, playing down suggestions he could use proceeds from a slew of asset sales for a significant takeover. Amid speculation Novartis might use proceeds to buy AstraZeneca or Bristol-Myers Squibb to fill holes in its cancer drug portfolio, Jimenez said he remained focused on smaller purchases of up to $5 billion to bolster his pipeline. "Obviously, there's been a lot of speculation because that would be a lot of capital," Jimenez said at an event at Novartis's research campus in Boston.
Indian drugmaker Lupin Ltd expects to launch over 30 products in the United States this year, but warned revenue growth would remain muted due to growing pricing pressure and competition in the world's largest healthcare market. "We've talked about medium single digits of price erosion in the past and I think we are now (seeing) high single digits," Managing Director Nilesh Gupta told Reuters after Lupin reported a quarterly profit that halved from a year earlier. The country's third-largest drugmaker has been working on building a pipeline of high-value complex generic drugs in the United States to offset growing competition in plain generics.
India's drug pricing regulator has demanded explanations from 65 domestic and global drugmakers for selling new forms of essential diabetes and antibiotic drugs without its approval. The move could bring penalties for the drugmakers, among them Abbott Laboratories, Sanofi, Novartis and Indian firms such as Sun Pharmaceutical Industries and Lupin, the National Pharmaceutical Pricing Authority (NPPA) said on its website.
Lupin Ltd.’s point man for mergers and acquisitions figures he has about $1 billion to work with as he hunts for targets to hasten the Indian firm’s move from simple generic drugs to more profitable products. ...